Ascendis Pharma/ASND

$155.44

-1.33%
-
1D1W1MYTD1YMAX

About Ascendis Pharma

Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

Ticker

ASND

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jan Moller Mikkelsen

Employees

879

Headquarters

Hellerup, Denmark

Ascendis Pharma Metrics

BasicAdvanced
$9.2B
Market cap
-
P/E ratio
-$9.26
EPS
0.54
Beta
-
Dividend rate

What the Analysts think about Ascendis Pharma

Analyst Ratings

Majority rating from 14 analysts.
Buy

Price Targets

Average projection from 13 analysts.
11.86% upside
High $227.54
Low $117.31
$155.44
Current price
$173.88
Average price target

Ascendis Pharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-63.03% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
€137.7M
186.88%
Net income
€-86.8M
-46.49%
Profit margin
-63.03%
-81.35%

Ascendis Pharma Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 24.02%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-€1.98
-€2.16
-€2.88
-€1.54
-
Expected
-€2.66
-€2.59
-€2.38
-€2.03
-€1.51
Surprise
-25.58%
-16.62%
21.08%
-24.02%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

Buy or sell Ascendis Pharma stock

Buy or sell Ascendis Pharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing